Experience of the use of genetically engineered biologic drugs in the treatment of rheumatoid arthritis after tofacitinib


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article is devoted to the actual problem - the change in the disease-modifying therapy of rheumatoid arthritis against the background of activity of the disease. The author gives his own observations concerning the management of patients after the cessation of therapy with the Janus kinase blocker tofacitinib. Based on four clinical examples, the selection of genetically engineered biological agents for the treatment of RA after the completion of therapy with tofacitinib administered due to the ineffectiveness of methotrexate is discussed.

全文:

受限制的访问

作者简介

I. Marusenko

FSBEI HE “Petrozavodsk State University"

Email: Imarusen-ko@yandex.ru
MD, Prof. at the Department of Hospital Therapy

参考

  1. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J.J., Haraoui B., Kalden J., Keystone E.C., Kvien T.K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010;69:631-37.
  2. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388:2023-38.
  3. Sokka T., Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430-32.
  4. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., Ramiro S., Winthrop K., de Wit M., Aletaha D., Betteridge N., Bijlsma J.W., Boers M., Buttgereit F., Combe B., Cutolo M., Damjanov N., Hazes J.M., Kouloumas M., Kvien T.K, Mariette X., Pavelka K., van Riel P.L., Rubbert-Roth A., Scholte-Voshaar M., Scott D.L., Sokka-Isler T., Wong J.B., van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann. Rheum. Dis. 2014;73:492-509.
  5. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита-2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013;51(6):609-22.
  6. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., Лукина Г.В., Жиляев Е.В., Амирджанова В.Н., Муравьев Ю.В., Чичасова Н.В. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России-2014» (часть 1). Научно-практическая ревматология. 2014;52(5):477-94.
  7. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., Gruben D., Wallenstein G.V., Zwillich S.H., Kanik K.S.; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheu-matoid arthritis. N. Engl. J. Med. 2012;367:495-507.
  8. Genovese M.C., Kremer J., Zamani O., Ludivico C., Krogulec M., Xie L., Beattie S.D., Koch A.E., Cardillo T.E., Rooney T.P., Macias W.L., de Bono S., Schlichting D.E., Smolen J.S. Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Ann. Rheum. Dis. 2015;74:75-6.
  9. Hazlewood G.S., Barnabe C., Tomilison G., Marshall D., Devoe D., Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systemic review and network meta-analysis. BMJ. 2016;353:i1777.
  10. Smolen J.S., Aletaha D. Rheumatoid arthritis therapy reappraisal: straregies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-89.
  11. Насонов Е.Л. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научно-практическая ревматология. 2016;54(5):557-71.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##